Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1435-4373
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Serious adverse events with novel beta-lactam/beta-lactamase inhibitor combinations: a large-scale pharmacovigilance analysis ; day:7 ; month:1 ; year:2021 ; pages:1-8
European journal of clinical microbiology & infectious diseases ; (7.1.2021), 1-8
- Classification
-
Medizin, Gesundheit
- Creator
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10096-020-04149-3
- URN
-
urn:nbn:de:101:1-2021020811092822627538
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:26 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gatti, Milo
- Raschi, Emanuel
- De Ponti, Fabrizio
- SpringerLink (Online service)
Other Objects (12)
Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
Genetic associations in beta-lactam allergy
![Neue semisynthetische β-Lactam-Antibiotika [Beta-Lactam-Antibiotika] aus Arylpyrrolidoncarbonsäuren](/assets/placeholder/searchResultMediaNoDigitisedMedia.png)
Neue semisynthetische β-Lactam-Antibiotika [Beta-Lactam-Antibiotika] aus Arylpyrrolidoncarbonsäuren
Potential involvement of beta-lactamase homologous proteins in resistance to beta-lactam antibiotics in gram-negative bacteria of the ESKAPEE group
Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy
Cefoxitin, ein β-Lactamase-stabiles [Beta-Lactamase-stabiles] Antibiotikum
β-Lactamase-Produktion [Beta-Lactamase-Produktion] durch Acinetobacter calcoaceticus
β [Beta]-Lactam-Synthesen mit siliciumorganischen Verbindungen
Synthese, Struktur und Reaktivität von neuen β-Lactam-Verbindungen [Beta-Lactam-Verbindungen]
Synthese und biologische Aktivität neuer nichtklassischer β-Lactam-Antibiotika [Beta-Lactam-Antibiotika]
Cephalosporins as key lead generation beta-lactam antibiotics
Predicting Oral Beta-lactam susceptibilities against Streptococcus pneumoniae
Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
Genetic associations in beta-lactam allergy
Neue semisynthetische β-Lactam-Antibiotika [Beta-Lactam-Antibiotika] aus Arylpyrrolidoncarbonsäuren
Potential involvement of beta-lactamase homologous proteins in resistance to beta-lactam antibiotics in gram-negative bacteria of the ESKAPEE group
Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy
Cefoxitin, ein β-Lactamase-stabiles [Beta-Lactamase-stabiles] Antibiotikum
β-Lactamase-Produktion [Beta-Lactamase-Produktion] durch Acinetobacter calcoaceticus
β [Beta]-Lactam-Synthesen mit siliciumorganischen Verbindungen
Synthese, Struktur und Reaktivität von neuen β-Lactam-Verbindungen [Beta-Lactam-Verbindungen]
Synthese und biologische Aktivität neuer nichtklassischer β-Lactam-Antibiotika [Beta-Lactam-Antibiotika]
Cephalosporins as key lead generation beta-lactam antibiotics
Predicting Oral Beta-lactam susceptibilities against Streptococcus pneumoniae
Rationale and evidence for the use of new beta-lactam/beta-lactamase inhibitor combinations and cefiderocol in critically ill patients
Genetic associations in beta-lactam allergy
Neue semisynthetische β-Lactam-Antibiotika [Beta-Lactam-Antibiotika] aus Arylpyrrolidoncarbonsäuren
Potential involvement of beta-lactamase homologous proteins in resistance to beta-lactam antibiotics in gram-negative bacteria of the ESKAPEE group
Risk factors for mortality of patients with ceftriaxone resistant E. coli bacteremia receiving carbapenem versus beta lactam/beta lactamase inhibitor therapy
Cefoxitin, ein β-Lactamase-stabiles [Beta-Lactamase-stabiles] Antibiotikum
β-Lactamase-Produktion [Beta-Lactamase-Produktion] durch Acinetobacter calcoaceticus
β [Beta]-Lactam-Synthesen mit siliciumorganischen Verbindungen
Synthese, Struktur und Reaktivität von neuen β-Lactam-Verbindungen [Beta-Lactam-Verbindungen]
Synthese und biologische Aktivität neuer nichtklassischer β-Lactam-Antibiotika [Beta-Lactam-Antibiotika]
Cephalosporins as key lead generation beta-lactam antibiotics